Company Overview

MADRIGAL PHARMACEUTICALS, INC.

MDGL
Annual
Revenue vs. Cost of Revenue
Revenue Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses Operating Income
Net Income
Net Income
Revenue
958M
2025 FY
Net Income
-288M
2025 FY
Shares Outstanding
22M
2025 FY
EPS
-12.85USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1157601
Exchange
Nasdaq
Location
US